Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis

We characterized the fatty acid profiles in the erythrocyte membrane of pediatric patients with cystic fibrosis (CF) receiving highly concentrated docosahexaenoic acid (DHA) supplementation (Tridocosahexanoin-AOX ® 70%) at 50 mg/kg/day (n = 11) or matching placebo (n = 11) for 12 months. The mean ag...

ver descrição completa

Detalhes bibliográficos
Autores: Ayats-Vidal, Roser|||0000-0002-5245-9847, Bosque, Montserrat|||0000-0001-5426-4034, Cordobilla, Begoña|||0000-0002-0418-9387, Asensio-De la Cruz, Oscar|||0000-0001-9304-3074, García-González, Miguel|||0000-0002-4330-7200, Castro-Marrero, Jesús|||0000-0002-2481-3052, López-Rico, Irene|||0000-0002-5886-7948, Domingo, Joan Carles|||0000-0002-6356-0836
Formato: artículo
Fecha de publicación:2023
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:290206
Acesso em linha:https://ddd.uab.cat/record/290206
https://dx.doi.org/urn:doi:10.3390/jcm12113704
Access Level:acceso abierto
Palavra-chave:Cystic fibrosis
Docosahexaenoic acid
Eicosapentaenoic acid
Fatty acids
Omega-3
Pancreatic insufficiency
Randomized controlled study
id ES_a5ffcf1439d1b415de8e29be41b0852b
oai_identifier_str oai:ddd.uab.cat:290206
network_acronym_str ES
network_name_str España
repository_id_str
spelling Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic FibrosisA Randomized Double-Blind Controlled TrialAyats-Vidal, Roser|||0000-0002-5245-9847Bosque, Montserrat|||0000-0001-5426-4034Cordobilla, Begoña|||0000-0002-0418-9387Asensio-De la Cruz, Oscar|||0000-0001-9304-3074García-González, Miguel|||0000-0002-4330-7200Castro-Marrero, Jesús|||0000-0002-2481-3052López-Rico, Irene|||0000-0002-5886-7948Domingo, Joan Carles|||0000-0002-6356-0836Cystic fibrosisDocosahexaenoic acidEicosapentaenoic acidFatty acidsOmega-3Pancreatic insufficiencyRandomized controlled studyWe characterized the fatty acid profiles in the erythrocyte membrane of pediatric patients with cystic fibrosis (CF) receiving highly concentrated docosahexaenoic acid (DHA) supplementation (Tridocosahexanoin-AOX ® 70%) at 50 mg/kg/day (n = 11) or matching placebo (n = 11) for 12 months. The mean age was 11.7 years. The DHA group showed a statistically significant improvement in n-3 polyunsaturated fatty acids (PUFAs), which was observed as early as 6 months and further increased at 12 months. Among the n-3 PUFAs, there was a significant increase in DHA and eicosapentaenoic acid (EPA). Additionally, a statistically significant decrease in n-6 PUFAs was found, primarily due to a decrease in arachidonic acid (AA) levels and elongase 5 activity. However, we did not observe any changes in linoleic acid levels. The long-term administration of DHA over one year was safe and well tolerated. In summary, the administration of a high-rich DHA supplement at a dose of 50 mg/kg/day for one year can correct erythrocyte AA/DHA imbalance and reduce fatty acid inflammatory markers. However, it is important to note that essential fatty acid alterations cannot be fully normalized with this treatment. These data provide timely information of essential fatty acid profile for future comparative research.Universitat Autònoma de Barcelona 22023-01-0120232023-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/290206https://dx.doi.org/urn:doi:10.3390/jcm12113704reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2902062026-06-06T12:50:31Z
dc.title.none.fl_str_mv Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis
A Randomized Double-Blind Controlled Trial
title Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis
spellingShingle Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis
Ayats-Vidal, Roser|||0000-0002-5245-9847
Cystic fibrosis
Docosahexaenoic acid
Eicosapentaenoic acid
Fatty acids
Omega-3
Pancreatic insufficiency
Randomized controlled study
title_short Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis
title_full Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis
title_fullStr Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis
title_full_unstemmed Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis
title_sort Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis
dc.creator.none.fl_str_mv Ayats-Vidal, Roser|||0000-0002-5245-9847
Bosque, Montserrat|||0000-0001-5426-4034
Cordobilla, Begoña|||0000-0002-0418-9387
Asensio-De la Cruz, Oscar|||0000-0001-9304-3074
García-González, Miguel|||0000-0002-4330-7200
Castro-Marrero, Jesús|||0000-0002-2481-3052
López-Rico, Irene|||0000-0002-5886-7948
Domingo, Joan Carles|||0000-0002-6356-0836
author Ayats-Vidal, Roser|||0000-0002-5245-9847
author_facet Ayats-Vidal, Roser|||0000-0002-5245-9847
Bosque, Montserrat|||0000-0001-5426-4034
Cordobilla, Begoña|||0000-0002-0418-9387
Asensio-De la Cruz, Oscar|||0000-0001-9304-3074
García-González, Miguel|||0000-0002-4330-7200
Castro-Marrero, Jesús|||0000-0002-2481-3052
López-Rico, Irene|||0000-0002-5886-7948
Domingo, Joan Carles|||0000-0002-6356-0836
author_role author
author2 Bosque, Montserrat|||0000-0001-5426-4034
Cordobilla, Begoña|||0000-0002-0418-9387
Asensio-De la Cruz, Oscar|||0000-0001-9304-3074
García-González, Miguel|||0000-0002-4330-7200
Castro-Marrero, Jesús|||0000-0002-2481-3052
López-Rico, Irene|||0000-0002-5886-7948
Domingo, Joan Carles|||0000-0002-6356-0836
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Cystic fibrosis
Docosahexaenoic acid
Eicosapentaenoic acid
Fatty acids
Omega-3
Pancreatic insufficiency
Randomized controlled study
topic Cystic fibrosis
Docosahexaenoic acid
Eicosapentaenoic acid
Fatty acids
Omega-3
Pancreatic insufficiency
Randomized controlled study
description We characterized the fatty acid profiles in the erythrocyte membrane of pediatric patients with cystic fibrosis (CF) receiving highly concentrated docosahexaenoic acid (DHA) supplementation (Tridocosahexanoin-AOX ® 70%) at 50 mg/kg/day (n = 11) or matching placebo (n = 11) for 12 months. The mean age was 11.7 years. The DHA group showed a statistically significant improvement in n-3 polyunsaturated fatty acids (PUFAs), which was observed as early as 6 months and further increased at 12 months. Among the n-3 PUFAs, there was a significant increase in DHA and eicosapentaenoic acid (EPA). Additionally, a statistically significant decrease in n-6 PUFAs was found, primarily due to a decrease in arachidonic acid (AA) levels and elongase 5 activity. However, we did not observe any changes in linoleic acid levels. The long-term administration of DHA over one year was safe and well tolerated. In summary, the administration of a high-rich DHA supplement at a dose of 50 mg/kg/day for one year can correct erythrocyte AA/DHA imbalance and reduce fatty acid inflammatory markers. However, it is important to note that essential fatty acid alterations cannot be fully normalized with this treatment. These data provide timely information of essential fatty acid profile for future comparative research.
publishDate 2023
dc.date.none.fl_str_mv 2
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/290206
https://dx.doi.org/urn:doi:10.3390/jcm12113704
url https://ddd.uab.cat/record/290206
https://dx.doi.org/urn:doi:10.3390/jcm12113704
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415661628817408
score 15.301603

Registos relacionados